Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 14/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ro-5027838 SCHEMBL2325156 | 0.95 | ALDH1A1 (0.36) | ALDH1A1HPGDHTTRORCBCHE | |
| Ro-5027838 SCHEMBL2328744 | 0.95 | ALDH1A1 (0.36) | ALDH1A1HPGDHTTRORCBCHE | |
| SCHEMBL16678323 | 0.78 | LMNA (0.39) | ALDH1A1HPGDHTTRORCBCHE | |
| SCHEMBL16678325 | 0.78 | LMNA (0.39) | ALDH1A1HPGDHTTRORCBCHE | |
| SCHEMBL2324559 | 0.77 | ALDH1A1 (0.36) | ALDH1A1HPGDHTTRORCBCHE | |
| SCHEMBL4493430 | 0.76 | ALDH1A1 (0.35) | ALDH1A1HPGDHTTRORCBCHE | |
| SCHEMBL11968315 | 0.76 | ALDH1A1 (0.35) | ALDH1A1HPGDHTTRORCBCHE | |
| SCHEMBL11968216 | 0.76 | LMNA (0.36) | ALDH1A1HPGDHTTRORCBCHE | |
| SCHEMBL4493682 | 0.76 | LMNA (0.36) | ALDH1A1HPGDHTTRORCBCHE | |
| SCHEMBL4484600 | 0.76 | ALDH1A1 (0.35) | ALDH1A1HPGDHTTRORCBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904455-B1 | PYRIDAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-17 | — | — | EP | claimed |
| US-7678795-B2 | Pyridazines as 11b-HSD1 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | claimed |
| US-20070010519-A1 | New pyridazines as 11B-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. | 2007-01-11 | — | — | US | claimed |
| EP-1904455-B1 | PYRIDAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-17 | — | — | EP | disclosed |
| US-7678795-B2 | Pyridazines as 11b-HSD1 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20070010519-A1 | New pyridazines as 11B-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010519-A1 | New pyridazines as 11B-HSD1 inhibitors | HSD11B1, HSD17B1, HSD17B11 | ALDH1A1 91/4885HPGD 92/4885HTT 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.